A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06717698 on ClinicalTrials.gov · last registry update 2026-03-11
An unusually large phase 2: 465 participants, more than double the 114 typical for the stage. Its estimated completion date, 1 September 2026, has passed with no update to the record. Primary outcome, as filed: Change in urinary albumin-to-creatinine ratio (UACR) at week 12. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for chronic kidney disease, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P2
- Drug
- semaglutideWegovy, Ozempic, Rybelsus
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 465
- Started
- 2024-12-02
- Primary completion
- 2026-09-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in urinary albumin-to-creatinine ratio (UACR) at week 12
Conditions studied
Chronic Kidney Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.